{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:07:49Z","timestamp":1791544069911,"version":"4.3.4"},"reference-count":63,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Medical advances in the management of patients with sickle cell disease, thalassemia, and other hemolytic anemias have led to significant increases in life expectancy. Improved public health, neonatal screening, parental and patient education, advances in red cell transfusion medicine, iron chelation therapy, penicillin prophylaxis for children, pneumococcal immunization, and hydroxyurea therapy have all likely contributed to this effect on longevity.1,2 Importantly, as a generation of patients with sickle cell disease and thalassemia ages, new chronic complications of these hemoglobinopathies develop. In this context, pulmonary hypertension is emerging as one of the leading causes of morbidity and mortality in adult sickle cell and thalassemia patients, and likely in patients with other hemolytic anemias. A common feature of both sickle cell disease and thalassemia is intravascular hemolysis and chronic anemia. Recent data suggest that chronic intravascular hemolysis is associated with a state of endothelial dysfunction characterized by reduced nitric oxide (NO) bioavailability, pro-oxidant and pro-inflammatory stress and coagulopathy, leading to vasomotor instability and ultimately producing a proliferative vasculopathy, a hallmark of which is the development of pulmonary hypertension in adulthood.3\u20135 In conclusion, pulmonary hypertension is common in patients with hereditary hemolytic anemias and is associated with a high risk of death in patients with sickle cell disease. New therapies targeting this vasculopathy and aimed at normalizing the vasodilator:vasoconstrictor balance are discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2005.1.51","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T01:29:34Z","timestamp":1132709374000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":76,"title":["Cardiopulmonary Complications of Sickle Cell Disease: Role of Nitric Oxide and Hemolytic Anemia"],"prefix":"10.1182","volume":"2005","author":[{"given":"Mark T.","family":"Gladwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703531830300_R1","doi-asserted-by":"crossref","unstructured":"Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762\u2013769.","DOI":"10.1056\/NEJM199709113371107"},{"key":"2019111703531830300_R2","doi-asserted-by":"crossref","unstructured":"Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645\u20131651.","DOI":"10.1001\/jama.289.13.1645"},{"key":"2019111703531830300_R3","doi-asserted-by":"crossref","unstructured":"Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383\u20131389.","DOI":"10.1038\/nm1202-799"},{"key":"2019111703531830300_R4","doi-asserted-by":"crossref","unstructured":"Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. Jama. 2005;293:1653\u20131662.","DOI":"10.1001\/jama.293.13.1653"},{"key":"2019111703531830300_R5","doi-asserted-by":"crossref","unstructured":"Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest. 2004;114:1136\u20131145.","DOI":"10.1172\/JCI200421633"},{"key":"2019111703531830300_R6","doi-asserted-by":"crossref","unstructured":"Wink DA, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med. 1998;25:434\u2013456.","DOI":"10.1016\/S0891-5849(98)00092-6"},{"key":"2019111703531830300_R7","doi-asserted-by":"crossref","unstructured":"Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524\u2013526.","DOI":"10.1038\/327524a0"},{"key":"2019111703531830300_R8","doi-asserted-by":"crossref","unstructured":"Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3\u2032:5\u2032-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A. 1977;74:3203\u20133207.","DOI":"10.1073\/pnas.74.8.3203"},{"key":"2019111703531830300_R9","doi-asserted-by":"crossref","unstructured":"Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res. 1987;61:866\u2013879.","DOI":"10.1161\/01.RES.61.6.866"},{"key":"2019111703531830300_R10","doi-asserted-by":"crossref","unstructured":"Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, Lemon DD. No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med. 2004;36:685\u2013697.","DOI":"10.1016\/j.freeradbiomed.2003.11.030"},{"key":"2019111703531830300_R11","doi-asserted-by":"crossref","unstructured":"Lancaster JR, Jr. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide. 1997;1:18\u201330.","DOI":"10.1006\/niox.1996.0112"},{"key":"2019111703531830300_R12","doi-asserted-by":"crossref","unstructured":"Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med. 2003;348:1483\u20131485.","DOI":"10.1056\/NEJMcibr023045"},{"key":"2019111703531830300_R13","doi-asserted-by":"crossref","unstructured":"Liao JC, Hein TW, Vaughn MW, Huang KT, Kuo L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci U S A. 1999;96:8757\u20138761.","DOI":"10.1073\/pnas.96.15.8757"},{"key":"2019111703531830300_R14","doi-asserted-by":"crossref","unstructured":"Vaughn MW, Kuo L, Liao JC. Effective diffusion distance of nitric oxide in the microcirculation. Am J Physiol. 1998;274:H1705\u20131714.","DOI":"10.1152\/ajpheart.1998.274.5.H1705"},{"key":"2019111703531830300_R15","doi-asserted-by":"crossref","unstructured":"Liu X, Miller MJ, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster JR, Jr. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem. 1998;273:18709\u201318713.","DOI":"10.1074\/jbc.273.30.18709"},{"key":"2019111703531830300_R16","doi-asserted-by":"crossref","unstructured":"Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107:271\u2013278.","DOI":"10.1161\/01.CIR.0000044943.12533.A8"},{"key":"2019111703531830300_R17","doi-asserted-by":"crossref","unstructured":"Eberhardt RT, McMahon L, Duffy SJ, et al. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol. 2003;74:104\u2013111.","DOI":"10.1002\/ajh.10387"},{"key":"2019111703531830300_R18","doi-asserted-by":"crossref","unstructured":"Nath KA, Shah V, Haggard JJ, et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1949\u20131955.","DOI":"10.1152\/ajpregu.2000.279.6.R1949"},{"key":"2019111703531830300_R19","doi-asserted-by":"crossref","unstructured":"Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol. 2000;278:H1799\u20131806.","DOI":"10.1152\/ajpheart.2000.278.6.H1799"},{"key":"2019111703531830300_R20","doi-asserted-by":"crossref","unstructured":"Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A. 2001;98:15215\u201315220.","DOI":"10.1073\/pnas.221292098"},{"key":"2019111703531830300_R21","doi-asserted-by":"crossref","unstructured":"Aslan M, Ryan TM, Townes TM, et al. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J Biol Chem. 2003;278:4194\u20134204.","DOI":"10.1074\/jbc.M208916200"},{"key":"2019111703531830300_R22","doi-asserted-by":"crossref","unstructured":"Pritchard KA, Jr., Ou J, Ou Z, et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2004;286:L705\u2013714.","DOI":"10.1152\/ajplung.00288.2002"},{"key":"2019111703531830300_R23","doi-asserted-by":"crossref","unstructured":"Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J. 2005;19:989\u2013991.","DOI":"10.1096\/fj.04-3218fje"},{"key":"2019111703531830300_R24","doi-asserted-by":"crossref","unstructured":"Gladwin MT, Lancaster JR, Jr., Freeman BA, Schechter AN. Nitric oxide\u2019s reactions with hemoglobin: a view through the SNO-storm. Nat Med. 2003;9:496\u2013500.","DOI":"10.1038\/nm0503-496"},{"key":"2019111703531830300_R25","doi-asserted-by":"crossref","unstructured":"Rybicki AC, Benjamin LJ. Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood. 1998;92:2594\u20132596.","DOI":"10.1182\/blood.V92.7.2594"},{"key":"2019111703531830300_R26","doi-asserted-by":"crossref","unstructured":"Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998;92:2551\u20132555.","DOI":"10.1182\/blood.V92.7.2551"},{"key":"2019111703531830300_R27","doi-asserted-by":"crossref","unstructured":"Hammerman SI, Kourembanas S, Conca TJ, Tucci M, Brauer M, Farber HW. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 1997;156:280\u2013285.","DOI":"10.1164\/ajrccm.156.1.9611085"},{"key":"2019111703531830300_R28","doi-asserted-by":"crossref","unstructured":"Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol. 2004;76:245\u2013251.","DOI":"10.1002\/ajh.20107"},{"key":"2019111703531830300_R29","doi-asserted-by":"crossref","unstructured":"Rivera A, Rotter MA, Brugnara C. Endothelins activate Ca(2+)-gated K(+) channels via endothelin B receptors in CD-1 mouse erythrocytes. Am J Physiol. 1999;277:C746\u2013754.","DOI":"10.1152\/ajpcell.1999.277.4.C746"},{"key":"2019111703531830300_R30","doi-asserted-by":"crossref","unstructured":"Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057\u20131058.","DOI":"10.1016\/S0140-6736(87)91481-4"},{"key":"2019111703531830300_R31","doi-asserted-by":"crossref","unstructured":"Setty BN, Stuart MJ, Dampier C, Brodecki D, Allen JL. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet. 2003;362:1450\u20131455.","DOI":"10.1016\/S0140-6736(03)14689-2"},{"key":"2019111703531830300_R32","doi-asserted-by":"crossref","unstructured":"Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294:81\u201390.","DOI":"10.1001\/jama.294.1.81"},{"key":"2019111703531830300_R33","doi-asserted-by":"crossref","unstructured":"Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886\u2013895.","DOI":"10.1056\/NEJMoa035477"},{"key":"2019111703531830300_R34","unstructured":"Morris CR, Morris SM, Jr., Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168:63\u201369."},{"key":"2019111703531830300_R35","doi-asserted-by":"crossref","unstructured":"Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 2002;99:1103\u20131108.","DOI":"10.1182\/blood.V99.4.1103"},{"key":"2019111703531830300_R36","doi-asserted-by":"crossref","unstructured":"Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639\u20131644.","DOI":"10.1056\/NEJM199406093302303"},{"key":"2019111703531830300_R37","doi-asserted-by":"crossref","unstructured":"Platt OS. Sickle cell anemia as an inflammatory disease [comment]. J Clin Invest. 2000;106:337\u2013338.","DOI":"10.1172\/JCI10726"},{"key":"2019111703531830300_R38","doi-asserted-by":"crossref","unstructured":"Kaul DK, Hebbel RP. Hypoxia\/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411\u2013420.","DOI":"10.1172\/JCI9225"},{"key":"2019111703531830300_R39","doi-asserted-by":"crossref","unstructured":"Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis associated priapism in sickle cell disease. Blood. 2005. Jun 28; [Epub ahead of print].","DOI":"10.1182\/blood-2005-04-1594"},{"key":"2019111703531830300_R40","doi-asserted-by":"crossref","unstructured":"Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101:1257\u20131261.","DOI":"10.1182\/blood-2002-03-0948"},{"key":"2019111703531830300_R41","doi-asserted-by":"crossref","unstructured":"Ataga KI, Sood N, De Gent G, et al. Pulmonary hypertension in sickle cell disease. Am J Med. 2004;117:665\u2013669.","DOI":"10.1016\/j.amjmed.2004.03.034"},{"key":"2019111703531830300_R42","doi-asserted-by":"crossref","unstructured":"Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127:1523\u20131530.","DOI":"10.1378\/chest.127.5.1523"},{"key":"2019111703531830300_R43","doi-asserted-by":"crossref","unstructured":"Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411\u20133416.","DOI":"10.1182\/blood.V97.11.3411"},{"key":"2019111703531830300_R44","doi-asserted-by":"crossref","unstructured":"Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JF. Pulmonary hypertension in sickle cell disease. Am J Cardiol. 1994;74:626\u2013628.","DOI":"10.1016\/0002-9149(94)90760-9"},{"key":"2019111703531830300_R45","doi-asserted-by":"crossref","unstructured":"Castro O. Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am. 1996;10:1289\u20131303.","DOI":"10.1016\/S0889-8588(05)70401-9"},{"key":"2019111703531830300_R46","doi-asserted-by":"crossref","unstructured":"Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol. 2002;33:1037\u20131043.","DOI":"10.1053\/hupa.2002.128059"},{"key":"2019111703531830300_R47","doi-asserted-by":"crossref","unstructured":"Derchi G, Fonti A, Forni GL, et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J. 1999;138:384.","DOI":"10.1016\/S0002-8703(99)70129-8"},{"key":"2019111703531830300_R48","doi-asserted-by":"crossref","unstructured":"Grisaru D, Rachmilewitz EA, Mosseri M, et al. Cardiopulmonary assessment in beta-thalassemia major. Chest. 1990;98:1138\u20131142.","DOI":"10.1378\/chest.98.5.1138"},{"key":"2019111703531830300_R49","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78:139\u2013145.","DOI":"10.1007\/BF02983382"},{"key":"2019111703531830300_R50","doi-asserted-by":"crossref","unstructured":"Chou R, DeLoughery TG. Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency. Am J Hematol. 2001;67:197\u2013199.","DOI":"10.1002\/ajh.1107"},{"key":"2019111703531830300_R51","doi-asserted-by":"crossref","unstructured":"Hayag-Barin JE, Smith RE, Tucker FC, Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol. 1998;57:82\u201384.","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<82::AID-AJH15>3.0.CO;2-B"},{"key":"2019111703531830300_R52","doi-asserted-by":"crossref","unstructured":"Aessopos A, Farmakis D, Deftereos S, et al. Cardiovascular effects of splenomegaly and splenectomy in beta-thalassemia. Ann Hematol. 2005;84:353\u2013357.","DOI":"10.1007\/s00277-004-1002-4"},{"key":"2019111703531830300_R53","doi-asserted-by":"crossref","unstructured":"Vichinsky EP. Pulmonary hypertension in sickle cell disease. N Engl J Med. 2004;350:857\u2013859.","DOI":"10.1056\/NEJMp038250"},{"key":"2019111703531830300_R54","unstructured":"Kietthubthew S, Kisanuki A, Asada Y, Marutsuka K, Funahara Y, Sumiyoshi A. Pulmonary microthrombo-embolism by injection of sonicated autologous blood in rabbits with splenic artery ligations. Southeast Asian J Trop Med Public Health. 1997;28 Suppl 3:138\u2013140."},{"key":"2019111703531830300_R55","doi-asserted-by":"crossref","unstructured":"Westerman, M., et al. Plasma \u2018free\u2019 HB is related to red cell derived vesicle numbers in sickle cell anemia and thalassemia intermedia: implications for nitric oxide (NO) scavenging and pulmonary hypertension. Blood2004;104(11):465a","DOI":"10.1182\/blood.V104.11.1671.1671"},{"key":"2019111703531830300_R56","doi-asserted-by":"crossref","unstructured":"Carnelli V, D\u2019Angelo E, Pecchiari M, Ligorio M. Pulmonary dysfunction in transfusion-dependent patients with thalassemia major. Am J Respir Crit Care Med. 2003;168:180\u2013184.","DOI":"10.1164\/rccm.200211-1292OC"},{"key":"2019111703531830300_R57","doi-asserted-by":"crossref","unstructured":"Tai DY, Wang YT, Lou J, Wang WY, Mak KH, Cheng HK. Lungs in thalassaemia major patients receiving regular transfusion. Eur Respir J. 1996;9:1389\u20131394.","DOI":"10.1183\/09031936.96.09071389"},{"key":"2019111703531830300_R58","doi-asserted-by":"crossref","unstructured":"Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore). 1988;67:66\u201376.","DOI":"10.1097\/00005792-198801000-00005"},{"key":"2019111703531830300_R59","doi-asserted-by":"crossref","unstructured":"De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension in SS, SC and Sbeta thalassemia: prevalence, associated clinical sydromes, and mortality [abstract]. Blood. 2004;104:462a.","DOI":"10.1182\/blood.V104.11.1663.1663"},{"key":"2019111703531830300_R60","doi-asserted-by":"crossref","unstructured":"Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005;130:445\u2013453.","DOI":"10.1111\/j.1365-2141.2005.05625.x"},{"key":"2019111703531830300_R61","doi-asserted-by":"crossref","unstructured":"Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol. 2005;129:449\u2013464.","DOI":"10.1111\/j.1365-2141.2005.05432.x"},{"key":"2019111703531830300_R62","unstructured":"Lin EE, Rodgers GP, Gladwin MT. Hemolytic anemia-associated pulmonary hypertension in sickle cell disease. Curr Hematol Rep. 2005;4:117\u2013125."},{"key":"2019111703531830300_R63","unstructured":"Lin EE, Gladwin MT, Machado RF. Pulmonary hypertension in patients with hemoglobinopathies: could a mechanism for dysfunction provide an avenue for novel therapeutics? Haematologica. 2005;90:441\u2013444."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/51\/645297\/051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/51\/645297\/051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:53:40Z","timestamp":1573980820000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2005\/1\/51\/19335\/Cardiopulmonary-Complications-of-Sickle-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2005.1.51","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}